How GLP-1 Treatment With sipra Works
Jillian Foglesong Stabile, MD
Board-certified Family Medicine · Diplomate, ABOM · Reviewed Jun 4, 2026
Most people picture a GLP-1 program as a single click and a box on the doorstep. The real process has more checkpoints than that, and the checkpoints are the point. They are what separate a careful provider from a risky one. By the end of this page you will know exactly what each step does, who reviews your case, and the two moments where you can stop the whole thing with zero penalty. The order matters. Here is the order.
The short answer
GLP-1 treatment with sipra works as a sequence: you complete a medical intake, a licensed physician reviews it, lab work is ordered when clinically appropriate through Junction Labs on the Quest backend, and if treatment is approved, a state-licensed 503A pharmacy prepares a patient-specific prescription. Physician follow-up is included. Individual results vary.
What you will learn
- The five stages of a GLP-1 program, in the order they happen
- Who actually reviews your case, and what they are checking for
- When lab work is ordered and why it gates the prescription
- What “503A patient-specific prescription” means for you
- The two points where you can cancel at any time with no charge and no phone call
- The questions to ask any provider before your card is on file
Chapter 01 · The intake
A careful GLP-1 program is a sequence of checks, not a checkout
Good GLP-1 care is built like a series of gates. Each gate has a job. Each gate can stop the process if something is off. Below is the whole path, stage by stage, so nothing about it is a surprise.
The five stages
A safe GLP-1 program moves through five stages: medical intake, physician review, lab work when indicated, a patient-specific prescription filled by a licensed pharmacy, and ongoing physician follow-up. No medication ships before a licensed physician approves it. You are not charged for treatment until that approval happens.
What is the first step in a GLP-1 program?
The first step is a structured medical intake. You answer questions about your health history, current medications, allergies, and goals. This is the data a physician uses to decide whether GLP-1 treatment is appropriate for you. It is detailed on purpose. The more complete it is, the safer the review.
A good intake asks about more than weight. It asks about your heart, your gut, your thyroid history, and your family history. It asks what other medications you take, because GLP-1 medications can interact with some of them. It asks about past surgeries and past reactions. None of this is busywork. Every question maps to a clinical decision a physician will make later.
The intake also sets a baseline. Your starting weight, your reported symptoms, and your stated goals become the reference point that every later check-in compares against. Without a baseline, there is nothing to measure progress or problems against.
A careful intake will sometimes route you away from GLP-1 treatment. A program that approves everyone is not really reviewing anyone.
Here is a quiet but important detail. A careful intake will sometimes route you away from GLP-1 treatment. If your answers raise a flag, the right outcome is a “not yet” or a “not a fit,” not a prescription anyway.
Chapter 02 · The review
Who reviews your case, and what they are checking
A licensed physician reviews your intake. They are checking three things at minimum: whether you have a condition that makes GLP-1 medication unsafe, whether your other medications interact with it, and whether your history points to a safer starting plan. This review is the gate that decides whether you go forward.
The contraindication check comes first. Certain histories, like a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, are listed by manufacturers as reasons not to use these medications. A physician screens for those before anything else.
Then comes the interaction check. GLP-1 medications slow how fast your stomach empties. That can change how other drugs are absorbed. A reviewer reads your full medication list with that in mind.
Last is the personalization read. Two people with the same weight can need very different starting plans based on their gut history, their other conditions, and how cautious their physician wants to be. The reviewer is reading for that, not just for a yes or no.
Chapter 03 · The labs
Lab work is the safety gate most people do not expect
People expect a form. People expect a doctor. Fewer people expect labs. But lab work is one of the most useful steps in the whole process, and skipping it is a warning sign about a provider.
Lab work is ordered when it is clinically appropriate, before or alongside the start of treatment. Through a sipra program, labs run through Junction Labs on the Quest Diagnostics backend. Results give your physician an objective read on your metabolic baseline, which can confirm the plan, adjust it, or pause it. Labs protect you.
When are labs ordered, and what do they show?
Labs are ordered when your physician decides your history calls for an objective baseline before treatment. Common panels look at metabolic markers, kidney and liver function, and other values that inform a safe plan. The results turn your self-reported history into measured data your physician can act on.
Think of labs as the difference between a description and a photograph. Your intake describes your health. Labs photograph part of it. A physician treating from both is in a far stronger position than one treating from the description alone.
There is a second reason labs matter. They create a record. If something changes three months in, your physician has a “before” number to compare against. That comparison is how problems get caught early instead of late.
Running labs through an established diagnostic backend matters too. Junction Labs uses the Quest Diagnostics network, which means standardized collection and reporting. The standard a patient should expect is a named, established lab partner, not a vague promise that “labs are handled.”
What would you actually pay?
30-second cost calculator
Chapter 04 · The prescription
Where compounded and branded paths split
This is the stage people misunderstand most. So slow down here. What gets prescribed, and how it is prepared, depends on your physician's clinical decision and what is appropriate for you.
If treatment is approved, your physician writes a prescription specific to you. That prescription can be for a branded GLP-1 medication or, in some cases, for a compounded preparation made by a state-licensed 503A pharmacy under your individual prescription. A 503A compounded medication is prepared for one named patient. It is not a generic version of a branded drug.
What does “503A patient-specific prescription” actually mean?
It means the medication is prepared by a state-licensed 503A compounding pharmacy for one specific, named patient, based on a prescription written for that person. It is not mass-produced. It is not sold off a shelf. It is not a generic. Each preparation traces back to an individual physician order.
The phrase has real legal weight. A 503A pharmacy compounds in response to an individual prescription for an individual patient. That is a different regulatory lane from a 503B outsourcing facility, which compounds larger batches from a federal bulk list. The distinction is in the news. On April 30, 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, citing no clinical need now that the shortages have resolved.1
Read this carefully
That April 2026 FDA proposal targets 503B bulk-list compounding. It does not change 503A patient-specific compounding, which is the lane a careful telehealth provider uses. The public comment window on the proposal closes June 29, 2026. Your 503A prescription is a distinct category.
So what should you actually demand from a provider here? Two things. First, a clear statement of whether your medication is branded or compounded. Second, if compounded, confirmation that it comes from a state-licensed 503A pharmacy under your own prescription. Any provider should answer both in plain language.
Chapter 05 · The follow-up
Follow-up is what separates a program from a transaction
Here is the part that gets sold short everywhere. Getting the medication is not the finish line. It is the start of the part that actually needs a clinician. The weeks after your first dose are when questions and side effects show up.
In a sipra program, physician follow-up is included, not sold as an add-on. After treatment starts, you have a channel to message your care team about side effects, dose tolerance, and progress. Any change to your plan is a physician decision, made with your reported experience in view. Follow-up is where care becomes ongoing instead of one-time.
What does physician follow-up include, and why does it matter?
Follow-up includes a way to report symptoms, a clinician who reads those reports, and physician-managed adjustments to your plan when they are warranted. It matters because the early weeks are when nausea, tolerance, and dose questions appear. Without follow-up, you are left to guess. With it, a clinician is guiding the next move.
Dose changes are a clinician's call, never a self-serve slider. Titration, the gradual approach to a maintenance plan, is managed by your physician based on how you respond. The right framing is simple. You report. They decide. That is what physician-managed means, and it is the only safe way to handle changes.
Follow-up also catches the quiet problems. A side effect you might shrug off could be a signal worth acting on. That second set of eyes is the entire value of support included.
Chapter 06 · The full picture
How the pieces fit: a plain-language walk-through
Now put the stages together, because the order is what keeps you safe. Each step feeds the next.
The sequence
A GLP-1 program runs in this order: intake first, physician review second, labs third when indicated, prescription fourth if approved, and follow-up fifth and ongoing. You can stop before any charge for treatment. No medication ships without physician approval, and you are not billed for treatment until a physician signs off.
Can I stop the process, and when?
Yes. There are two clear stop points before any treatment charge. You can decline after intake, before review. You can decline after review, before a prescription is filled. With a transparent provider, no treatment charge happens until a physician approves your plan, so stopping early costs you nothing.
This is where billing practices either earn trust or destroy it. The standard you should demand is plain. No charge for treatment until a physician approves you. A clear recurring price shown before checkout. One-click cancellation with no phone call required. If a provider cannot state all three, that silence is your answer.
A quick myth bust. You have to call and argue to cancel a GLP-1 subscription. With a well-built provider you do not. Cancellation should be a setting in your account, not a phone tree. The number of providers that fail this exact test is the reason it is worth checking before you sign up.
What does it cost, and how is billing handled?
Costs vary by medication and provider, and the GLP-1 pricing landscape shifted hard in 2026. Through most-favored-nation deals, direct-to-consumer injectable prices for Wegovy® and Zepbound® dropped to around $350 per month, with initiation doses near $199, down from prior list prices around $1,000 to $1,350. A Medicare GLP-1 Bridge begins July 1, 2026, with a flat $50 monthly copay for eligible beneficiaries.5
Around half of GLP-1 users report struggling with affordability, which is exactly why upfront pricing matters so much.2 A provider that hides the lab fee, the titration cost, or the cancellation terms is hiding the parts that hurt later.
The billing standard
Whatever the price, a good provider states it fully before checkout: the medication price, any consultation or membership fee, what happens at each dose change, and what you pay if you pause or stop. Recurring monthly charge until canceled. Cancel at any time in your account. No phone call required. No charge until your physician approves treatment.
| What to confirm | The standard to demand | Red flag if missing |
|---|---|---|
| Full medication price | Stated before checkout, all tiers | Surprise charges after signup |
| Lab cost | Disclosed separately, named partner | Vague “labs are handled” |
| Titration cost | Stated at each dose step | Unlisted fees at dose change |
| Cancellation policy | Account setting, no phone call | Requires a call to cancel |
| When you are charged | Only after physician approval | Card charged before review |
A provider that cannot answer all five columns is missing a piece that matters. Confirm in writing before your card is on file.
Chapter 07 · The 2026 picture
More options in 2026, same process discipline
The medications are multiplying, but the process around them should not change. A new pill or a new agonist still needs an intake, a review, and follow-up.
The GLP-1 field expanded fast in 2026. Oral options arrived: Novo's oral Wegovy® was approved in December 2025, and Lilly's orforglipron, sold as Foundayo™, reached roughly 12.4% average weight loss at its top dose in Phase III, compared with about 13.7% for injectable Wegovy®. Individual results vary. More choices are good. The discipline of intake, review, labs, and follow-up is what keeps any of them safe.3
12.4%
average weight loss on orforglipron (Foundayo™) top dose, Phase III (individual results vary)
13.7%
average weight loss on injectable Wegovy®, Phase III comparator (individual results vary)
Phase III trial group averages, not personal promises. Individual results vary.
What about newer drugs like retatrutide?
Retatrutide is an investigational triple agonist that is not approved. In the Phase III TRIUMPH-1 trial announced May 21, 2026, it reached up to 30.3% average weight loss at the highest dose and longest follow-up. Individual results vary. Because it is investigational, it is not something a provider can prescribe today.4
The takeaway is not the headline number. It is that even the most promising pipeline drug will still need the same process: a physician reading your history, labs when indicated, and follow-up after you start. New molecules do not replace the gates. They pass through them.
One more 2026 trend deserves a careful word: microdosing. A survey of more than 8,000 GLP-1 users found about 15% had tried microdosing, and the social media culture around it is loud. But UCLA and Mayo clinicians note there is no clinical definition and no evidence base for it. Any dose decision belongs with your physician, not a social feed.6
The standard worth holding any provider to
A good GLP-1 provider shows you the full monthly cost, the lab cost, the titration cost, and the cancellation policy before your card is charged. The intake is real, the physician review is not a rubber stamp, lab work runs through a named diagnostic partner, and follow-up is included, not sold separately. If a brand cannot tell you all of those things clearly, that tells you something. (This is the standard sipra is built around.)
You know the process. Here is how to move.
You do not need to commit to anything to get oriented. You need to know what a careful process looks like and hold your provider to it.
- Read the standard. Walk through the provider trust checklist and the first GLP-1 consultation guide so you know what a real intake and review include before you start.
- Check the billing terms. Confirm the full monthly cost, the lab cost, and the cancellation policy in writing before your card is on file.
- Look at what comes after the prescription. The part most providers skip is support. Ask directly: is physician follow-up included, or an add-on? Included is the standard.
This is educational content, not a diagnosis or a dose recommendation. A licensed clinician decides what is right for you.
Lose weight with a plan made just for you
- Same-day doctor visits and prescriptions
- Semaglutide, tirzepatide & other GLP-1s
- FSA & HSA eligible with all plans
From$79/mo
+ Sipra membership*
*Price includes medication only. Active $99/mo Sipra membership required.
Frequently asked questions
Sources
- U.S. Food and Drug Administration. "FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List." April 30, 2026. fda.gov
- KFF (Kaiser Family Foundation). "KFF Health Tracking Poll: the public’s views on GLP-1 drugs and affordability." 2026. kff.org
- Eli Lilly and Company. "FDA Approves Lilly’s Foundayo (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions." Press release, 2026. lilly.com
- AJMC. "Retatrutide Achieves Up to 30.3% Average Weight Loss in Phase 3 TRIUMPH-1 Trial." May 21, 2026. ajmc.com
- AJMC. "Trump Announces Deals With Eli Lilly, Novo Nordisk for Lower Weight Loss Drug Prices." Updated 2026. ajmc.com
- STAT News. "GLP-1 microdosing is trending. Clinicians say there is no evidence behind it." May 29, 2026. statnews.com
Trademark attribution. Wegovy® is a registered trademark of Novo Nordisk A/S. Zepbound® and Foundayo™ are trademarks of Eli Lilly and Company. sipra is not affiliated with or endorsed by these companies.
Medically reviewed by
Jillian Foglesong Stabile, MD, FAAFP, DABOM
Was this helpful?
Keep reading
Weight LossWhy Billing Transparency Should Be Your #1 Provider Filter
11 min read
Weight LossGLP-1 weight loss 101: how semaglutide and tirzepatide actually work
17 min read
Weight LossThe Real Cost of GLP-1 Medication: Every Number Before Your Card Is Charged
16 min read
Weight LossBranded vs compounded GLP-1s: the real difference in 2026
9 min read
Weight LossGLP-1 Myths That Won't Die (and the Facts That Beat Them)
9 min read
Weight LossGLP-1 Side Effects and How to Manage Them, Week by Week
10 min read
Weight LossHow GLP-1s work in the body: the science of appetite and satiety
9 min read
Weight LossWhat 503A compounding means (and why your prescription is made for you)
11 min read